London, UK – [Insert Date] – In a significant strategic shift, British pharmaceutical giant GSK has announced the discontinuation of its late-stage development program for camlipixant in the treatment of refractory chronic cough (RCC). The decision, which casts a shadow over a potential $1 billion market opportunity, follows mixed results from pivotal Phase III clinical trials and a reassessment of the drug’s ability to "transform patient care." While this marks a setback for GSK’s ambitions in the chronic cough space, the company is reaffirming its commitment to camlipixant by continuing its development for two distinct forms of irritable bowel syndrome (IBS).
n
The news arrives as GSK’s substantial $2 billion acquisition bid for Bellus Health, a key player in the chronic cough therapeutic area, is under intense scrutiny. The termination of the camlipixant RCC program introduces a new layer of complexity to this significant financial maneuver.
n
The Clinical Conundrum: Mixed Signals in Refractory Chronic Cough Trials
n
The decision to pull the plug on camlipixant for RCC is directly linked to the outcomes of the Phase III CALM-1 and CALM-2 studies. These large-scale, global trials were designed to evaluate the efficacy and safety of camlipixant, a P2X3 receptor antagonist, in patients suffering from chronic cough that does not respond to conventional treatments.
n
The CALM-1 study, which enrolled approximately 200 participants across numerous international sites, initially offered a glimmer of hope. A dosage of 50mg of camlipixant administered twice daily demonstrated statistically significant reductions in coughing frequency over a 24-hour period when compared to a placebo at the 12-week mark. This met the primary endpoint of the trial, suggesting a potential therapeutic benefit.
n
However, the subsequent CALM-2 study, conducted specifically in China, yielded a starkly different outcome. In this trial, camlipixant failed to replicate the positive results observed in CALM-1, failing to show a significant impact on cough frequency. This geographical disparity in efficacy raised immediate concerns about the drug’s broader applicability and the consistency of its therapeutic effect.
n
Further complicating the picture, a lower dose of camlipixant, 25mg twice daily, proved ineffective in both the CALM-1 and CALM-2 studies. This lower dose not only failed to demonstrate a significant reduction in cough frequency but also did not show a meaningful impact on secondary endpoint measures.
n
GSK’s internal assessment, based on these findings, concluded that while camlipixant exhibited a generally safe and tolerable profile, its efficacy in treating refractory chronic cough was deemed "limited." This led to the difficult but decisive step of terminating the late-stage development program for this indication.
n
A Strategic Pivot: Embracing the Potential in Irritable Bowel Syndrome
n
Despite the disappointing turn of events in the chronic cough arena, GSK is not abandoning camlipixant entirely. The company has signaled a strong commitment to exploring the drug’s therapeutic potential in other significant unmet medical needs, specifically in two distinct forms of irritable bowel syndrome (IBS).
n
GSK is currently advancing the Phase IIb BALANCE trial (NCT07519395) to investigate camlipixant’s efficacy in IBS. This trial is designed to assess the drug’s impact on the symptoms and underlying mechanisms of this prevalent gastrointestinal disorder. The BALANCE trial is projected to conclude in March 2027, according to data available on ClinicalTrials.gov.
n
This strategic pivot underscores GSK’s adaptive approach to drug development, seeking to maximize the value of its pipeline assets by redirecting promising candidates to therapeutic areas where they may demonstrate greater clinical utility and commercial viability. The IBS market, characterized by a significant patient population and a persistent need for novel treatment options, presents a substantial opportunity for camlipixant.
n
The Broader Landscape of P2X3 Receptor Antagonists: A Challenging Class
n
The discontinuation of camlipixant for RCC places it among a growing list of P2X3 receptor antagonists that have faced significant hurdles in this specific indication. The P2X3 receptor pathway has emerged as a promising target for cough suppression, as these receptors are believed to play a crucial role in mediating the cough reflex. However, the development of drugs targeting this pathway has been fraught with challenges related to efficacy and safety.
n
Prior to GSK’s decision, other major pharmaceutical players have also encountered difficulties with their P2X3 receptor antagonists. In 2022, Bayer announced the cessation of its development program for eliapixant, another P2X3 receptor antagonist, citing concerns regarding the drug’s safety profile. Earlier, Bayer had also discontinued the development of filapixant, another compound in the same class, due to a higher incidence of taste-related side effects observed in clinical trials.
n
Shionogi, a Japanese pharmaceutical company, also appears to have halted the development of its P2X3 receptor antagonist, sivopixant. The drug is no longer featured in the company’s current pipeline. However, Shionogi is actively pursuing a different avenue through a collaboration with Apnimed. This partnership focuses on the joint development of SASS-01, a novel therapeutic combining sivopixant with an undisclosed second compound, specifically aimed at treating sleep apnea.
n
The current therapeutic landscape for refractory chronic cough is marked by a significant unmet need. There are currently no medications approved by the U.S. Food and Drug Administration (FDA) specifically for the treatment of RCC. Patients typically rely on off-label use of existing medications, such as neuromodulators like gabapentin or tricyclic antidepressants, which often provide only partial relief and can be associated with significant side effects.
n
While MSD’s (Merck & Co.) P2X3-targeting therapy, Lyfnua (gefapixant), has received regulatory approval in several key markets including the UK, EU, Japan, and Switzerland, its path to market in the United States has been blocked. The FDA has notably refused to grant approval for gefapixant, citing concerns about its perceived lack of efficacy in the target patient population. This regulatory stance by the FDA further underscores the challenges in demonstrating robust and consistent clinical benefit for P2X3 receptor antagonists in the RCC indication.
n
Implications for GSK and the Pharmaceutical Industry
n
The decision to discontinue camlipixant in RCC represents a significant financial and strategic blow to GSK. The market for refractory chronic cough is estimated to be a potential multi-billion dollar opportunity, and the termination of this late-stage program effectively relinquishes a substantial portion of that potential. Analysts at Jefferies have estimated that this move rules out a "potential $1bn opportunity" for GSK in the RCC space.
n
However, the impact on GSK’s overall financial outlook may be mitigated by the company’s recent aggressive focus on strategic deals and collaborations. These initiatives are designed to bolster its revenue potential and diversify its pipeline, potentially absorbing the setback from the camlipixant RCC program. The company’s ongoing commitment to camlipixant in IBS also suggests a belief in the drug’s underlying scientific rationale and its potential to address other significant patient needs.
n
For the broader pharmaceutical industry, the challenges encountered by camlipixant and other P2X3 receptor antagonists in the RCC space highlight the complexities of developing treatments for chronic cough. The inconsistent trial results and regulatory hurdles faced by these compounds underscore the need for further research into the underlying mechanisms of chronic cough and the development of more robust clinical trial designs. The therapeutic landscape for RCC remains largely unaddressed, with significant demand for innovative and effective treatments.
n
The success or failure of camlipixant in the IBS trials will be closely watched by the industry. A positive outcome could not only salvage a valuable asset for GSK but also validate the P2X3 receptor antagonist class for other inflammatory and functional gastrointestinal disorders, potentially opening up new avenues for research and development in this area. The ongoing pursuit of treatments for chronic cough and IBS continues to be a critical focus for pharmaceutical innovation, driven by the persistent need to improve the lives of patients suffering from these debilitating conditions.
nnnnnnn
